Clinical Trials Logo

Filter by:
NCT ID: NCT00242801 Completed - NSCLC Clinical Trials

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

Start date: July 2003
Phase: Phase 3
Study type: Interventional

This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.

NCT ID: NCT00242775 Completed - Asthma Clinical Trials

Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg

Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.

NCT ID: NCT00242541 Terminated - Acromegaly Clinical Trials

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Start date: March 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy of octreotide acetate to decrease GH and IGF-I levels in acromegalic patients, with microadenomas (≤ 10 mm) or macroadenomas (> 10 mm).

NCT ID: NCT00241449 Completed - Breast Cancer Clinical Trials

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Start date: November 1998
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

NCT ID: NCT00240643 Completed - Atrial Fibrillation Clinical Trials

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.

NCT ID: NCT00240383 Completed - Clinical trials for Diabetes Mellitus II

Dose Ranging Study With LT, Monotherapy, PPAR

Start date: May 2002
Phase: Phase 2/Phase 3
Study type: Interventional

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

NCT ID: NCT00240370 Completed - Type 2 Diabetes Clinical Trials

A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics

Start date: October 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate if type 2 diabetics who have inadequate glycemic control on metformin alone, have a similar, or not inferior, glycemic response when treated with the combination of muraglitazar and metformin compared to pioglitazone and metformin.

NCT ID: NCT00240331 Completed - Renal Failure Clinical Trials

AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.

NCT ID: NCT00239967 Completed - Obesity Clinical Trials

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

ADAGIO-lipids
Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese patients with atherogenic dyslipidemia (low HDL and/or high TG plasma levels). The secondary objectives are to evaluate specific metabolic parameters, visceral fat (in selected sites), safety and tolerability of rimonabant 20 mg.

NCT ID: NCT00239681 Terminated - Clinical trials for Elevated High-sensitivity C-Reactive Protein (hsCRP)

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.